New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV DiseaseBusiness Wire • 10/24/24
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)Zacks Investment Research • 10/15/24
GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment ZantacThe Guardian • 10/09/24
GSK Reports Sustained Efficacy of RSV Vaccine Amidst Competition from Pfizer and ModernaGuruFocus • 10/08/24